8 results about "Hyperammonemia" patented technology

The invention provides an application of a component A as or used for preparing an SIRT5 inducer, the component A at least comprises one or more than two of ergothioneine, ectoine and hyaluronic acid or salt thereof, and the component A can be used for the SIRT5 inducer or used for preparing an SIRT5 expression inducer, so that cell aging can be inhibited, and the SIRT5 inducer can be used for preparing an SIRT5 expression inducer. The traditional Chinese medicine composition is used for improving natural skin aging, cardiac hypertrophy and / or hyperammonemia.

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.

The present disclosure provides implantable engineered tissue constructs having hepatocytes and stromal cells for the treatment of hyperammonemia.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a mangnolia officinalis extract or a structural analogue thereof in preparation of a medicament for treating hyperinsulinemia / hyperamminemia syndrome. The invention provides a new application of a mangnolia officinalis extract represented by honokiol. Research shows that the mangnolia officinalis extract or the structural analogue thereof can well inhibit the activity of glutamate dehydrogenase (GDH), including wild type GDH and GDH capable of causing acquisition function mutation of the hyperinsulinemia / hyperamminemia (HI / HA) syndrome, so that the effect of the mangnolia officinalis extract or the structural analogue thereof as a GDH inhibitor in treatment of the HI / HA syndrome is expanded, and the application of the mangnolia officinalis extract or the structural analogue thereof in treatment of the HI / HA syndrome is promoted. Effective attempts are made for solving the problem that existing medicines for treating the rare HI / HA syndrome are rare, the current situation of treating the HI / HA syndrome can be remarkably improved, the situation of lack of targeted medicines is broken through, the life quality of patients is improved, and the family and social burden of the patients is greatly relieved.

The invention belongs to the technical field of biological medicines, and relates to application of a histone deacetylase inhibitor HDACi in preparation of a medicine for preventing and / or treating hyperammonemia-induced encephalopathy. According to the invention, a histone deacetylase inhibitor HDACi is used as a new medicine, the HDACi can enter a central nervous system, and the GS is triggered to be degraded through a proteasome mediated by CRBN E3 ubiquitin ligase by improving the acetylation level of a key enzyme, namely glutamine synthetase (GS), of astrocytes, so that the GS protein abundance is reversibly reduced, and the GS protein abundance is reduced. The application has the advantages that pathological accumulation of toxic metabolite glutamine can be reduced from the source, cerebral edema, autophagy-lysosomal dysfunction, neuroinflammation and neuron injury caused by the pathological accumulation can be synchronously improved, severe neurotoxicity such as persistent enzyme inhibition and acute epilepsy caused by irreversible inhibitors such as MSO can be avoided, clinical transformation risks can be obviously reduced, and the safety is high.

The application relates to the field of biological medicine, in particular to application of sodium tiglate in preparation of products for promoting liver regeneration and reducing blood ammonia; it is found and disclosed for the first time in the application that sodium tiglate can be applied to preparation of liver regeneration or liver function recovery products, liver cell proliferation capacity of residual liver after partial hepatectomy can be improved by using sodium tiglate, blood ammonia level after liver surgery is controlled, nitrogen metabolism disorder is improved by promoting conversion of blood ammonia into urea, and liver cell regeneration capacity is improved; the application of sodium tiglate provides a new treatment strategy with clear action mechanism and wide development prospect for treatment of insufficient liver regeneration after partial hepatectomy and hyperammonemia.